Therapeutic Administration of the Scrambled Anti-Angiogenic Peptide C16Y
Posted Mar 31 2004 4:00pm
Description of Invention: This application relates to the field of anti-angiogenesis. In particular, the application describes and claims compositions and methods useful for treating diseases associated with angiogenesis such as macular degeneration (AMD), diabetic retinopathy, neovascular glaucoma and cancers associated with solid tumors particularly, breast cancer. The compositions and methods offer alternatives to other ocular anti-angiogenic agents currently in development due to their ease of manufacture and mode of action on an integrin pathway.
The compositions and methods utilize a synthetic peptide of between 8 and 12 amino acid residues derived from a region of the gamma1 chain of laminin-1 that binds to endothelial cell integrins alphavbeta3 and alpha5beta1. The preferred embodiment, designated C16Y, is 12 amino acids in length and is easily prepared by conventional peptide synthesis. The anti-angiogenic properties of the C16Y peptide have been demonstrated in an in vitro model of choroidal neovascularization and in tumor-bearing mice.
Inventors: Karl G Csaky (NEI) Lourdes Ponce (NEI) Hynda K Kleinman (NIDCR) Jeremy Wolfe (NEI)
Portfolios: Cancer Cancer - Therapeutics Ophthalmology Ophthalmology - Therapeutics
For Additional Information Please Contact: Susan Rucker J.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 30A, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-4478 Fax: 301-402-0220